Intellia Therapeutics (NTLA): New Data Implies Clinical Benefit - Wedbush
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Wedbush analyst, David Nierengarten, reiterated his Outperform rating on shares of Intellia Therapeutics (NASDAQ: NTLA) after additional data presented on its TTR program which the analyst thinks should correlate to clinical benefit.
On Thursday NTLA presented data showing they were able to achieve up to 60% editing of transthyretin (TTR) gene in the livers of mice following IV administration, which resulted in up to 80% decrease in TTR serum protein levels; this high editing rate was shown to be consistent across individual mice in a study and across liver lobes.
NTLA had previously presented data showing high levels of dose-dependent TTR editing in the liver cells of mice, and he expects to see further improvements in editing efficiency with continued guide RNA optimization. Although early, these results are meaningful and compare favorably with TTR serum reduction achieved by RNAi programs in development, which he notes are associated with only a transient benefit.
No change to the price target of $38.
Shares of Intellia Therapeutics closed at $22.30 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Galena Biopharma (GALE) PT Raised to $4 at Maxim Group into San Antonio Breast Cancer Symposium
- Oppenheimer Cuts Price Target on Workday (WDAY) Following 3Q; Reiterates Outperform
- Jefferies Cuts Price Target on PG&E Corp. (PCG) to $65 Following Rate Case Decision
Create E-mail Alert Related CategoriesAnalyst Comments, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!